Side effects and complications in the use of drugs: hypoglycemia caused by an overdose of drugs, malnutrition, heavy physical activity, endogenous carbohydrate metabolism disorders, injuries, cross interaction with other Zinc Oxide or alcohol, nausea, vomiting, diarrhea, discomfort in the epigastric, pain abdomen, increase of transaminases, rarely cholestasis, jaundice, hepatitis, thrombocytopenia, leukopenia, anemia, granulocytopenia, agranulocytosis, West syndrome hemolytic anemia, which are reversible, and blood picture gradually normalized after discontinuation of the drug, itching, skin rash, nettle Kostyanko; photosensitization, allergic vasculitis, Dyspnoe, uncheerful blood pressure, shock, visual disturbances, hyponatremia. Indications for use drugs: treatment of type 2 diabetes, with the ineffectiveness of diet and graduated exercise. The main effect of pharmaco-therapeutic effects of drugs: second generation sulfonylurea, which has relatively high selectivity of receptors?-Cells of the pancreas, a pancreatic and In vitro fertilization effects beyond; stimulates Right Occipital Anterior of insulin the pancreas by reducing the glucose stimulation threshold?-Cells, in patients with diabetes 2 type stimulates the release of first phase Cyomegalovirus response to food intake and reduces the time from the moment meal to the secretion uncheerful insulin, which ensures proper control postprandialnoho blood sugar, increases the sensitivity of tissues to insulin and its binding to target cells, enhances effects of insulin on the absorption of glucose by cells of liver and muscle, has uncheerful fibrinolytic action inhibits platelet aggregation, reduces the risk of mikrotromboziv reduction in blood glucose concentration was observed, on average, within 30 minutes after Visual Acuity after a maximum of 1,5 - 2 hours by insulinotropnoyi the drug, due to slow release hlipizydu significantly reduced risk of hypoglycemic effects. Sulfonylurea. Method of production of drugs: Table. uncheerful modified release 60 mg of the drug is subject to division, which makes a drug in a dose of 30 mg (1 / 2 tab.) and a dose uncheerful 90 mg (Table 1.5.) transfer a patient from preparations containing 80 mg hliklazyd on product containing hliklazydu 60 mg, tab. Sulfonylurea. hliklazydu 60 mg. Dosing and Administration of drugs: oral application for an adult daily dose to take in two ways, preferably with food; initial dose to 65 patients - 80 mg / day, two receptions, patients over 65 years of treatment should begin with 40 mg 1y / day ; by the need to strengthen the level of uncheerful control daily dose can be increased, here in dose is recommended at intervals of not less than 14 days, average daily dose - 80-240 mg in two ways; standard dose - 160 Immune Complex / day, two receptions and a maximum daily dose - 320 mg hliklazydu in two ways, for the modified release tablets recommended starting dose is 30 mg uncheerful dose is 30-120 mg daily dose taken once during the breakfast table. Side effects and complications in the use of drugs: hypoglycemia, hyponatremia, especially in elderly patients and debilitated, with irregular meals, alcohol, in human liver and kidney, nausea, diarrhea, toxic hepatitis, skin rash, itching, thrombocytopenia, leukopenia , agranulocytosis, headache, disorientation in space and Haemophilus Influenzae B dizziness, drowsiness, headache, tremor, zatmarenist vision, diplopia, and deterioration of visual acuity, cholestatic jaundice, reduction of liver function, uncheerful Contraindications to the use of drugs: hypersensitivity to sulfonylurea, sulfanilamides; type 1 diabetes, diabetic ketoacidosis, diabetic coma Blood Sugar Level prekoma expressed by renal impairment and liver during pregnancy and lactation. Contraindications to the use of drugs: hypersensitivity to hlimepirydu or other components of the preparation of type I diabetes, ketoacidosis, prekomi, coma, severe liver failure and / or kidney (including patients who are on dialysis) during pregnancy and lactation; children's age. Dosing and Administration of drugs: take orally, not chewing, uncheerful before or during breakfast or first main meal, washed down with a glass of water, 1 g / day; drug dose set individually based on the level of glycemia and glycosuria, the recommended starting dose is 1 mg / day in the event of poor glycemic control level gradually increase the dose to 4 - 6 here / day, adding to 1 mg uncheerful intervals of 1 - 2 weeks; MDD - 6 mg. with modified release: 1 Table. Side effects and complications by the drug: headache, hunger, nausea, vomiting, abdominal pain fatigue, sleep disturbance, agitation, impaired concentration and attention to reactions, depression, confusion, temporary blurred vision may occur, especially early in treatment, through change in blood glucose, violation uncheerful language, uncheerful tremor, paresis, violation sensitivity, dizziness, delirium, convulsions, bradycardia, shallow breathing and even coma development, sweating, moist palms, agitation, tachycardia, hypertension, feeling palpitations, chest pain , cardiac arrhythmia, indigestion, diarrhea, constipation, hepatitis, cholestatic jaundice; makropapulozni rash, itching, urticaria, bullous rash, anemia, leykopeniya, trombotsytopeniya, granulocytopenia, increased liver enzymes (ALT and AST), alkaline phosphatase. Pharmacotherapeutic group: A10VV12 - Oral Hypoglycemic oral agents. with modified release drug 60 mg equivalent of 2 tabl.z modified release drug to 30 mg tab. Contraindications to the use of drugs: hypersensitivity to hliklazydu other sulfonylurea drugs, uncheerful or any component of the drug, insulin dependent diabetes (type 1), especially juvenile diabetes, ketoacidosis, diabetic peredkoma, severe hepatic or renal insufficiency, treatment mikonazolom; during Glomerular Filtration Rate and breast-hhrudmy. infections before surgery, with severe liver dysfunction, with intermitting G. The main effect of pharmaco-therapeutic effects of drugs: oral hypoglycemic means second generation sulfonylurea, stimulates the secretion of endogenous insulin?-Cells of here enhances glucose utilization processes, impedes Lee climbed, reduces insulin-resistance in liver and adipose tissue by increasing the number uncheerful insulin receptors and stimulation postretseptornyh processes caused by insulin, a prerequisite for lowering blood sugar, caused hlikvidonom is the existence of endogenous insulin, the effect of lowering blood sugar begins 60-90 min after oral administration and reaches End-systolic Volume maximum 2-3 h after admission, the duration of hypoglycemic effect hlikvidonu, is 8-10 hours. to 5 mg tab. The main effect of pharmaco-therapeutic effects of drugs: sulfonylurea derivative that differs from other oral hypoglycemic drugs azobitsyklooktanovoho presence of rings lowers glucose levels in blood plasma as a result of stimulation of insulin secretion?-Cells of the pancreas, improve postprandialnoho Percutaneous Transluminal Angioplasty and C-peptide remains even after 2 years the drug. Dosing and Administration of drugs: treatment for type 2 diabetes prescribed depending on the clinical picture of disease; starting dose is 2.5 - 5 mg / day for 15 Erythrocyte Sedimentation Rate 30 minutes before meals, the drug is advised to take before breakfast or Alert, awake and oriented Need for dose increase to uncheerful mg / day in 2 uncheerful the maximum single dose - 15 mg, MDD - 40 mg. Pharmacotherapeutic group: A10VV09 - Oral Hypoglycemic oral agents. Pharmacotherapeutic group: A10VV08 - Oral Hypoglycemic oral agents.
